JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Minneapolis, Aug. 09, 2016 -- PetVivo Holdings, Inc. (OTC-PETV), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced an investment research report on the Company. The initiation of coverage report provides a comprehensive overview of the Company and its industry, along with a company valuation relative to its peer group. The sponsored research report also carries a rating and a price target.
In the report released today, Marble Arch Research notes that, “PetVivo Holdings is well-positioned to emerge as the standard of care for the treatment of osteoarthritis in dogs and horses, an estimated $3.2 billion combined annual market. Moreover, we believe that once full scale commercialization occurs in the coming months, PetVivo could enjoy hockey stick-type revenue growth.”
About Marble Arch Research, Inc.:
Marble Arch Research is a leading Independent Equity Research provider with a global reach. Headquartered in Atlanta, the Company also has offices in London and New York. Marble Arch Research’s sponsored research services are geared to those companies that may not yet be on many investors’ radar, or are seeking broad investor awareness through research coverage, valuation analysis, and global distribution to the institutional investment community. With over 75 years of combined investment experience, all research is written by independent analysts including former Wall Street veterans of major investment banks and mutual fund managers.
A Marble Arch Research report, update, newsletter, article, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Marble Arch Research is not a registered investment adviser or broker-dealer with FINRA or any other agency. Please refer to the reports disclosures and disclaimers for more information. Marble Arch Research was compensated by the Company for this research subscription service.
Contact: Michael Price, [email protected]
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
PetVivo’s Corporate Presentation can be found here:
http://petvivo.com/wp-content/uploads/2016/04/PetVivo-Corp-Deck-04-01-16.pdf
Forward-Looking Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
John Lai
Chief Executive Officer
PetVivo Holdings, Inc.
Email: [email protected]
Phone: 612-296-7305
